Tinea capitis: diagnostic criteria and treatment options

Area of Science:

• Dermatology
• Mycology
• Pharmacology

Background:

• Tinea capitis, or scalp ringworm, is a fungal infection affecting the hair shaft.
• It predominantly impacts pediatric populations, necessitating systemic antifungal therapy over topical options.
• Current FDA-approved treatments include griseofulvin and terbinafine, with treatment durations of 6-8 weeks and 6 weeks, respectively.

Purpose of the Study:

• To review the current research literature on pharmacologic treatments for tinea capitis.
• To compare the efficacy and duration of FDA-approved versus off-label medications.
• To inform clinical practice regarding optimal treatment strategies for tinea capitis.

Main Methods:

• Literature review of research-based studies on tinea capitis pharmacologic treatment.
• Analysis of cure rates and treatment durations for various antifungal agents.
• Identification of FDA-approved and off-label medications used for tinea capitis.

Main Results:

• Griseofulvin and terbinafine are the primary FDA-approved systemic antifungals for tinea capitis.
• Several non-FDA-approved medications demonstrate comparable cure rates to griseofulvin and terbinafine.
• These off-label agents often provide shorter treatment durations, leading to their common use.

Conclusions:

• Systemic antifungal therapy is essential for treating tinea capitis.
• Off-label medications represent a viable alternative to FDA-approved drugs, potentially offering improved patient compliance due to shorter treatment courses.
• Further research may support expanded FDA approval for effective off-label agents in tinea capitis treatment.